Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change % Change Share Price Shares Traded Last Trade
  9.40 3.1% 312.60 1,338,505 16:35:25
Bid Price Offer Price High Price Low Price Open Price
311.40 311.80 312.80 306.60 308.20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 584.92 140.50 20.71 13.7 2,196
Last Trade Time Trade Type Trade Size Trade Price Currency
17:46:09 O 6,770 312.60 GBX

Indivior (INDV) Latest News (7)

More Indivior News
Indivior Investors    Indivior Takeover Rumours

Indivior (INDV) Discussions and Chat

Indivior Forums and Chat

Date Time Title Posts
24/6/202215:35INDIVIOR THE PILL WITH NO CHEERS OR BEERS3,504
09/3/202010:34RB. de-merger 548
11/7/201908:29Johnson & Johnson court case oklahoma6
03/5/201910:16Judgement against insys2
31/7/201813:45Indivior (INDV) IP Battle Status -

Add a New Thread

Indivior (INDV) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Indivior trades in real-time

Indivior (INDV) Top Chat Posts

DateSubject
25/6/2022
09:20
Indivior Daily Update: Indivior Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker INDV. The last closing price for Indivior was 303.20p.
Indivior Plc has a 4 week average price of 274p and a 12 week average price of 274p.
The 1 year high share price is 340p while the 1 year low share price is currently 143.60p.
There are currently 702,438,801 shares in issue and the average daily traded volume is 1,919,473 shares. The market capitalisation of Indivior Plc is £2,195,823,691.93.
23/6/2022
12:12
gibbs1: INDIVIOR PLC (INDV) Real-time Estimate Cboe Europe - 07:11 2022-06-23 am EDT 300.20 GBX +2.81%
01/6/2022
15:04
timmy11: Indivior Announces First Patient Included in Aelis Farma's Phase 2b Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects With Moderate to Severe Cannabis Use Disorder 01/06/2022 2:50pm PR Newswire (US) Indivior (LSE:INDV) Intraday Stock Chart Wednesday 1 June 2022 Click Here for more Indivior Charts. SLOUGH, England and RICHMOND, Va., June 1, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) announces the enrollment of the first patient in the Phase 2b study of AEF0117 for the treatment of cannabis use disorder (CUD). This follows less than a year after Indivior and Aelis Farma announced a strategic collaboration that includes an exclusive option and license agreement for the global rights to AEF0117, a first-in-class synthetic Signaling Specific Inhibitor ("SSI") engineered to inhibit the cannabinoid type 1 ("CB1") receptor ("CB1-SSI").
27/5/2022
11:06
waldron: Indivior to Participate in Jefferies 2022 Healthcare Conference Slough, UK and Richmond, VA - May 24, 2022 - Indivior PLC (LON: INDV) today announced that Mark Crossley, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will participate in the Jefferies 2022 Healthcare Conference in New York City. Mark Crossley will present on June 8, 2022, at 8:00 AM (US ET). The live presentation will be available on Indivior's website www.indivior.com and can also be viewed using the following webcast link: Https://wsw.com/webcast/jeff240/indv.l/2067675 . About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .
09/5/2022
12:21
casholaa: INDV are very shrewd and/or have some excellent advisors. I do wonder how low they may think the share price may go for the buyback. These people are just stellar in every respect. Respect to them!
03/5/2022
20:31
youngers: Yes of course because when the share price is over £3 per share you’d announce a buy back if you didn’t want to pay £3 😂 I’ve been looking for similar sized and growth US stocks and I’m coming up with a US value around $7.50. In my mind this has a long way to go yet. DYOR
03/5/2022
09:49
waldron: 3 May 2022 Indivior Announces Share Repurchase Program Details Slough, UK and Richmond, VA, 3 May, 2022 - Indivior PLC (LON: INDV) today announced that, as outlined in its Q1 results on 28 April 2022, it will commence a share repurchase program of Indivior's ordinary shares (the "Ordinary Shares") for up to a maximum consideration of $100 million (the "Program"). Indivior PLC ("Indivior") announces that it has entered into a non-discretionary agreement with Stifel Nicolaus Europe Limited ("Stifel") in relation to the Program and for Stifel to carry out on-market purchases, acting as riskless principal, during the period commencing on 3 May, 2022 and ending no later than 31 March, 2023, of the Ordinary Shares and the simultaneous on-sale of such Ordinary Shares by Stifel to Indivior.
04/4/2022
09:23
florenceorbis: 31 March 2022 Indivior to Commence Formal Shareholder Consultations on Additional US Listing Richmond, VA, March 31, 2022 - Indivior PLC, (LON: INDV) today announced that further to its announcement on February 16, 2022, it is commencing formal consultations with shareholders on the potential for an additional listing of Indivior shares in the US on a major stock exchange. The Board believes that an additional US listing is likely to be beneficial to elevating the Group's profile in its largest market. In coming to its view, the Board considered the following key elements of the Group's strategy, structure and opportunity: -- Approximately 80% of Group's net revenue is generated in the US; -- The US currently is, and is expected to remain, the Group's largest and highest value market for its key treatments (SUBLOCADE (R) and PERSERIS (R) ); -- Healthcare comprises approximately 20% of US gross domestic product (GDP) and, as such, the US contains the largest pool of biopharma-focused investors and research analyst coverage; -- The CEO and a majority of the Group's leadership team are based in the US; -- 40%-plus of shareholders are based in North America; and -- Provides a US stock currency for potential business development. The Board looks forward to receiving investor feedback during the consultations and, if supportive, the Board intends to put forward a formal shareholder resolution in September of this year that would facilitate an additional listing in the US. Comment by Graham Hetherington, Chair of the Board In assessing Indivior's optimal listing structure, the Board's approach is always to consider what is in the best interests of the Group and all of its stakeholders over the long-term. The Board believes that an additional US listing in the near-term would be beneficial because we believe it will raise the Group's profile in its highest value market and potentially attract a broader group of biopharma shareholders. Longer-term, it also provides the Group with the optionality to pursue a primary or sole US listing, if appropriate. We have received initial positive feedback from a broad range of shareholders on the potential of an additional US listing. We are, however, mindful that this is a complex issue for shareholders, and we look forward to commencing a period of formal consultations with our shareholders. We will listen carefully to all shareholder feedback and expect to make a further announcement following the conclusion of shareholder consultations, which is likely to be in July of this year in conjunction with the Group's H1 2022 results. Background In conjunction with its FY 2021 results release on February 16, 2022, the Group's Board indicated that it had been assessing the optimal listing structure for Indivior shares and that its preliminary view was that an additional listing of Indivior shares on a major US stock exchange is likely to be beneficial to the Group's profile and ability to attract a broader group of biopharma-focused investors and research analysts. The Board is now formally commencing further consultations with institutional shareholders on the potential of such an additional US listing. More detail on the US additional listing considerations can be found in the Consultation presentation on the Group's website. If supported by shareholders, the key considerations and anticipated timings for an additional US listing are as follows: -- Additional listing of Indivior shares on a major US stock exchange (i.e., NASDAQ, NYSE); -- Full premium London Stock Exchange listing maintained; -- FTSE indexation maintained; -- Requires shareholder approval by a majority of 75% (of votes cast) of a resolution to amend Indivior's articles of association to facilitate settlement of its shares in the UK and US; -- Extraordinary General Meeting of shareholders to obtain such approval in September 2022; and -- Earliest implementation of additional US listing in Spring 2023.
12/3/2022
17:05
typo56: The news is quite possibly a continuation of this from 23 Feb.. "Indivior, the FTSE 250-listed opiod addiction treatment company, is rumoured to be the mystery bidder circling Opiant Pharmaceuticals, the US-listed developer of medicines for drug addiction. People following the situation have heard rumours Indivior has been talking to Opiant since December last year year about a possible offer for the company." Good or bad for the INDV share price? You decide!
12/3/2022
15:29
waldron: Stocks Here's Why "Trend" Investors Would Love Betting on Indivior PLC (INVVY) Contributor Zacks Equity Research Zacks Published Mar 7, 2022 8:50AM EST Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- that could keep the momentum in the stock going. Investors looking to make a profit from stocks that are currently on the move may find our "Recent Price Strength" screen pretty useful. This predefined screen comes handy in spotting stocks that are on an uptrend backed by strength in their fundamentals, and trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness. There are several stocks that passed through the screen and Indivior PLC (INVVY) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing. A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. INVVY is quite a good fit in this regard, gaining 19% over this period. However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that might have happened in a shorter time frame. It's important for a potential winner to maintain the price trend. A price increase of 21.5% over the past four weeks ensures that the trend is still in place for the stock of this company. Moreover, INVVY is currently trading at 89.4% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout. Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock's near-term price movements. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Another factor that confirms the company's fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock's near-term price performance. So, the price trend in INVVY may not reverse anytime soon.
15/1/2021
17:52
grupo guitarlumber: Indivior is the biggest FTSE 250 gainer today. Would I buy it now? Manika Premsingh | Friday, 15th January, 2021 Business development to success and FTSE 100 250 350 growth concept. The FTSE 250 opioid addiction treatment provider Indivior (LSE: INDV) is the biggest index gainer today as I write. Its share price is up 9%, continuing its recovery after a sharp fall in late November. Why the share price rose INDV’s better-than-expected financial results are the clear reason for the uptick in share price. It now expects revenue to be at least $25m higher than it had expected earlier for the full year. It also expects expenses to be lower, resulting in an improved income forecast. What’s next for the INDV share price I reckon that the latest news will provide continued impetus for INDV’s share price. It’s now at 115p, up from the sub-100p levels it was at before the last week of December. The big decline started in late November, when it crashed 30% in a day following news that its former parent company — Reckitt Benckiser — had filed a £1bn claim on it. Even now the share price is still much lower than its 131p levels at the time. But at least it’s now closer than ever to getting back there. When I last wrote about Indivior, after its share price fall, my sense was that its share price would be dependent more on its own performance than anything else. If the share price reaction to its latest results is anything to go by, it only proves the point I was making at the time. If its performance remains consistent, I reckon that its share price can climb up further. This is especially so in today’s bullish market, where investors are rewarding companies that are performing well. Battling the opioid crisis Moreover, the seriousness of the opioid crisis is big and rising, an issue that Indivior is well placed to address. According to the World Health Organisation, globally 0.5m deaths are caused by drug use every year, of which 70% are opioid-related. Moreover, between 2010 and 2018, the number of people dying of opioid overdose in the US increased by 120%. Past problems still haunt Despite this, as an investor I’m cautious because of INDV’s problems from the recent past, which include accusations of mis-selling and resulted in its former CEO being imprisoned. Almost two months after I wrote about INDV, it indeed appears to have put the episode behind it. It has also said that Reckitt Benckiser’s claim is without merit. Further, its financials had suffered quite the blow in the first nine months of 2020, with a sharp decline in revenue. The latest numbers, then, are a surprise development and not one that reflects the inherent, ongoing strength of the company. I think the INDV stock looks much better after its results than it did two months ago when it was far more in the thick of a crisis. It could continue to see improvements from here. But I really want to see some more predictability to its financials before buying the stock. Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned.
Indivior share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
INDV
Indivior
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220625 21:04:25